Ribupatide
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Completed · Enrollment 249
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Treatment group A | n/r | n/r | n/r | n/r | n/r |
| Treatment group B | n/r | n/r | n/r | n/r | n/r |
| Treatment group C | n/r | n/r | n/r | n/r | n/r |
| Treatment group D | n/r | n/r | n/r | n/r | n/r |
| Treatment group E | n/r | n/r | n/r | n/r | n/r |
| Treatment group F | n/r | n/r | n/r | n/r | n/r |
| Treatment group G | n/r | n/r | n/r | n/r | n/r |
| Treatment group H | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.